loading page

Mineralocorticoid receptor in cardiovascular diseases -- clinical trials and mechanistic insights
  • Johann Bauersachs,
  • Natalie López Andrés
Johann Bauersachs
Medizinische Hochschule Hannover

Corresponding Author:[email protected]

Author Profile
Natalie López Andrés
Author Profile


Aldosterone binds to the mineralocorticoid receptor (MR), a transcription factor of the nuclear receptor family, present in the kidney and in various other non-epithelial cells including the heart and the vasculature (Cannavo et al., 2018). Indeed, extra-renal pathophysiological effects of this hormone have been characterized, extending its actions to the cardiovascular (CV) system (Messaoudi et al., 2012). A growing body of clinical and pre-clinical evidence suggests that MR activation plays an important pathophysiological role in CV remodeling by promoting cardiac hypertrophy, fibrosis, arterial stiffness, as well as in inflammation and oxidative stress (Bauersachs et al., 2015). The following review article outlines the role of MR in CV disease with a focus on myocardial remodeling and heart failure (HF) including clinical trials as well as cellular and animal studies.
18 Jun 2021Submitted to British Journal of Pharmacology
18 Jun 2021Submission Checks Completed
18 Jun 2021Assigned to Editor
04 Jul 2021Reviewer(s) Assigned
31 Jul 2021Review(s) Completed, Editorial Evaluation Pending
02 Aug 2021Editorial Decision: Revise Minor
07 Sep 20211st Revision Received
07 Sep 2021Submission Checks Completed
07 Sep 2021Assigned to Editor
09 Sep 2021Reviewer(s) Assigned
23 Sep 2021Review(s) Completed, Editorial Evaluation Pending
27 Sep 2021Editorial Decision: Accept
Jul 2022Published in British Journal of Pharmacology volume 179 issue 13 on pages 3119-3134. 10.1111/bph.15708